Caris Life Sciences and Ono Pharmaceutical Co., Ltd. announced a strategic collaboration to leverage Caris' best-in-class molecular profiling, including its novel, liquid biopsy circulating nucleic acids sequencing (cNAS) assay, across several studies beginning later this year. Under the terms of the agreement, Caris will provide comprehensive molecular profiling analysis in support of several Ono clinical studies evaluating a range of targeted and immune-based therapies, including an initial phase III trial, and others to be named at a later date. Caris' cNAS molecular profiling assesses all 22,000 genes across DNA and RNA from blood, which are unique to an individual's cancer, to reveal a molecular blueprint in order to guide more precise and individualized treatment decisions.